BK posted an email with Leo that mentioned 500m sale of P after a successful p2 and 2.5b after p3. Personally, I would take the p2 and if lucky enough to get 500m, focus on B and their numerous applications and K's applications. That's enough to keep them busy for the decade or more. Be the REGN where they develop the drug then hand it off for others to finish up.

I agree with you. Who knows what the real numbers would be but that's a good way to look at it.